These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

670 related items for PubMed ID: 23896656

  • 1. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
    Gill U, Aziz H, Gill ML.
    Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
    [Abstract] [Full Text] [Related]

  • 2. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
    Aziz H, Raza A, Waheed Y, Gill U, Gill ML.
    Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
    [Abstract] [Full Text] [Related]

  • 3. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW, Wang GQ, Sun LJ, Li XG, Li SC.
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [Abstract] [Full Text] [Related]

  • 4. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W.
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [Abstract] [Full Text] [Related]

  • 5. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.
    Dogan UB, Atabay A, Akin MS, Yalaki S.
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1082-5. PubMed ID: 23524524
    [Abstract] [Full Text] [Related]

  • 6. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
    Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P, Austrian Hepatitis Study Group.
    Gastroenterology; 2008 Aug; 135(2):451-8. PubMed ID: 18503773
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan.
    Aziz H, Gil ML, Waheed Y, Adeeb U, Raza A, Bilal I, Athar MA.
    Infect Genet Evol; 2011 Apr; 11(3):640-5. PubMed ID: 21316487
    [Abstract] [Full Text] [Related]

  • 8. A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C.
    Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Rajender Reddy K.
    J Hepatol; 2012 May; 56(5):1012-1018. PubMed ID: 22266603
    [Abstract] [Full Text] [Related]

  • 9. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
    Shea DO, Tuite H, Farrell G, Codd M, Mulcahy F, Norris S, Bergin C.
    J Viral Hepat; 2008 Jul; 15(7):482-9. PubMed ID: 18221297
    [Abstract] [Full Text] [Related]

  • 10. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
    Bonardi R, Tabone M, Manca A, Pellicano R, Ciancio A, Rizzetto M.
    Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
    [Abstract] [Full Text] [Related]

  • 11. Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin.
    Dogan UB, Akin MS, Yalaki S.
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1317-20. PubMed ID: 23680912
    [Abstract] [Full Text] [Related]

  • 12. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.
    Hlaing NK, Banerjee D, Mitrani R, Arker SH, Win KS, Tun NL, Thant Z, Win KM, Reddy KR.
    World J Gastroenterol; 2016 Nov 21; 22(43):9613-9622. PubMed ID: 27920482
    [Abstract] [Full Text] [Related]

  • 13. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].
    Liu JP, Kang Y, Shang J, Ding GQ, Xiao EH, Wei JF, Cao Q.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Sep 21; 21(9):656-8. PubMed ID: 24160338
    [Abstract] [Full Text] [Related]

  • 14. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
    Kikuchi K, Akiba T, Nitta K, Masakane I, Ando R, Izumi N, Atsukawa M, Yamazaki C, Kato F, Hotta N, Tominaga Y, Orito E, Hora K, Nagasawa M, Kasahara H, Kawaguchi M, Kimura H, Ikebe N, Kawanishi H, Moriishi M, Shigemoto K, Harada T, Hirakata H, Watanabe H, Nosaki T, Tsubouchi H, Imawari M, Akizawa T.
    Ther Apher Dial; 2014 Dec 21; 18(6):603-11. PubMed ID: 25196061
    [Abstract] [Full Text] [Related]

  • 15. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
    Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL.
    Hepatology; 2008 Jun 21; 47(6):1884-93. PubMed ID: 18508296
    [Abstract] [Full Text] [Related]

  • 16. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F, SMIEC II Investigators.
    Eur J Gastroenterol Hepatol; 2008 Jul 21; 20(7):680-7. PubMed ID: 18679072
    [Abstract] [Full Text] [Related]

  • 17. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
    Sarrazin C, Schwendy S, Möller B, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Prinzing R, Herrmann E, Zeuzem S, Berg T.
    Gastroenterology; 2011 Nov 21; 141(5):1656-64. PubMed ID: 21784046
    [Abstract] [Full Text] [Related]

  • 18. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N, Giannelli G, Antonaci A, Antonaci S.
    J Viral Hepat; 2008 Apr 21; 15(4):300-4. PubMed ID: 18307592
    [Abstract] [Full Text] [Related]

  • 19. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.
    Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P, Austrian Hepatitis Study Group.
    Gastroenterology; 2010 Feb 21; 138(2):503-12, 512.e1. PubMed ID: 19909752
    [Abstract] [Full Text] [Related]

  • 20. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.
    Pattullo V, Ravindran NC, Mazzulli T, Wong DK, Heathcote EJ.
    J Viral Hepat; 2010 Dec 21; 17(12):834-8. PubMed ID: 20196800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.